ePharmaSolutions Joins the WIRB-Copernicus Group
New addition expands WCG's eClinical offerings for improving clinical trial start-up and management
WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that ePharmaSolutions (ePS) has joined its group of companies. Based near Philadelphia, PA, ePS is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials. Its proprietary solutions, including a cloud-based enterprise Clinical Trial Portal (CTP) and Electronic Trial Master File (eTMF), are used by 350,000 clinical research professionals in 130 countries who benefit from the improved coordination of study start up, site management, and regulatory document control.
“We are delighted to welcome ePharmaSolutions into the WCG family of companies. WCG and ePharmaSolutions share a powerful vision of how to improve clinical research trials – a cornerstone in the mission of WCG,” said WCG Chairman and CEO Donald A. Deieso, Ph.D. “Using ePS’ leading technology-driven solutions to assure that the activities of trial sites are coordinated, well informed, and efficiently managed will result in significant benefits to pharmaceutical companies, contract research organizations (CROs), institutions, and subjects.”
“Joining WCG will fulfill our company’s enormous potential as a beneficial force in the conduct of clinical trials,” said ePS Founder and CEO Lance Converse. “We look forward to contributing our technology and clinical support services to the broader mission of WCG – industry transformation,” he added. September has been an important month for our company; in addition to the WCG transaction, we were pleased to have been chosen as the winner of the ‘Disruptive Innovator of the Year’ award during the fourth annual Dpharm: Disruptive Innovations to Advance Clinical Trials conference – a recognition by leading industry professionals of the value of our work. ”
Like the other companies within WCG, ePharmaSolutions will continue to operate independently at its current locations, and will retain both its leadership and brand. WCG will support ePharmaSolutions as it continues to expand its platform solution with access to capital, complementary clinical expertise, corporate support, and integration of its technologies within the WCG family of companies.
ePharmaSolutions joins Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, Aspire IRB, New England IRB, and IRBNet as a member of the WCG family of companies.
Financial details about the transaction were not disclosed.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
